MedPath

Instillation of Gentamicin and Dexamethasone in Bronchiectasis Compared to Conventional Treatment

Phase 4
Recruiting
Conditions
Bronchiectasis With Acute Exacerbation
Interventions
Registration Number
NCT06209047
Lead Sponsor
Assiut University
Brief Summary

Safety and efficacy of local instillation of Gentamicin and dexamethasone in acute exacerbation of bronchiectasis in mechanically ventilated patients

Detailed Description

bronchiectasis is a chronic suppurative and inflammatory lung disease of diverse etiology characterized by pathological and irreversible dilatation of the bronchial tree. The impairment of the mucociliary clearance, which results from chronic airway inflammation, may cause long-term colonization or recurrent infection of bacteria, especially Pseudomonas aeruginosa (PA), while bacterial colonization and recurrent infection can aggravate airway inflammation. Sputum retention caused by the impairment of mucociliary clearance can result in mucous plugs, which in turn contribute to airflow obstruction and dyspnea.

Clinically, the major manifestations of bronchiectasis are chronic cough with purulent sputum, dyspnea, and fatigue that may diminish the patients' quality of life. The frequency of exacerbation and the decline in lung function may lead to poor prognosis and decrease quality of life.

The purpose of bronchiectasis management is to reduce exacerbation, prevent complications, and improve the quality of life. Long-term instillation of gentamicin can reduce the concentration of bacteria in the airways, decrease sputum production, attenuate lung function decline, and reduce acute pulmonary exacerbations without nephrotoxicity or ototoxicity. Dexamethasone is one of the most common glucocorticoids which can inhibit the expression levels of inflammatory factors in the airway and reduce the secretion of airway mucus. Topical administration could also reduce the systemic side effects.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • patients with bronchiectasis confirmed by high resolution CT chest(HRCT)
  • patients with acute exacerbation of bronchiectasis who need antibiotic treatment at hospital due to exacerbation
  • mechanically ventillated patients at respiratory ICU
  • Age more than or equal 18 years
Exclusion Criteria
  • patients with active pulmonary tuberculosis
  • patients with allergic bronchopulmonary aspergillosis
  • patients who underwent interventional bronchoscopy for hemoptysis
  • age less than 18 years

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
drug groupbronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasonethis arm will include half number of cases(which will be 35 cases) selected in a randomized manner and will undergo bronchoscopic airway clearance followed by local instillation of gentamicin(80 mg once) and dexamethasone(5 mg) once.
Primary Outcome Measures
NameTimeMethod
The amount of sputum production per day(ml/day)one year

the total amount of sputum per day will be measured and compared between drug and conventional groups

Days for weaning from mechanical ventilationone year

days of mechanical ventilation will be measured and compared between drug and conventional groups

Secondary Outcome Measures
NameTimeMethod
Days of intensive care unit(ICU) and hospital stayone year

days of ICU and hospital stay will be measured

days for recurrenceone year

days for recurrence or next exacerbation will be measured

Trial Locations

Locations (1)

Assiut university hospitals

🇪🇬

Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath